Mumbai, June 18 -- The company's dossier compiled under EU guidelines have fetched this second approval in continuation to the journey of their research-driven API-integrated EU GMP approved oncology formulation manufacturing unit.

While the earlier product intends to treating breast cancer, non-small cell lung cancer and prostate cancer, this second one is for treating colorectal cancer; both are widely prevalent type of cancers.

"Strategically the second MA now widens the door to export and commercialise injection products to the European countries, with the first MA that received approval in April-2025 is in process of its FIRST commercial supply," Sakar Healthcare stated.

It further said that with another few products (mix of liqui...